RxDoctor Payments Data

Naeem Chaudhry, MD

Internal Medicine · Elmhurst, NYNPI 1790850998

Payments from drug & device makers

$2,033in general payments, 2019–2025

Across 38 payments — averaging $53.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$878
  • AstraZeneca$380
  • Medtronic$125
  • E.r. Squibb & Sons, L.L.C.$125
  • Akebia Therapeutics Inc$124
  • Abbott$94
  • plus $307 from 9 others

What the payments were for

  • Speaking & faculty fees$231%
  • Food & beverage$2,00599%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,033 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$626,834
Medicare patients
576
Services billed
8,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban530$167,877
JardianceEmpagliflozin101$43,544
JanuviaSitagliptin Phosphate68$31,903
Sevelamer Carbonate40$29,641
XareltoRivaroxaban74$23,917
ArexvyRsvpref3 Antigen/As01e/Pf78$23,480
SantylCollagenase Clostridium Hist.32$17,774
NuedextaDextromethorphan Hbr/Quinidine24$16,252
JanumetSitagliptin Phos/Metformin Hcl40$15,970
Mirtazapine422$13,026
Memantine Hcl281$12,349
RetacritEpoetin Alfa-Epbx37$12,248
Atorvastatin Calcium710$12,080
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog112$9,871
ErtapenemErtapenem Sodium21$8,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$13$180,125567 claims
Johnson & JohnsonXarelto$878$23,91774 claims
Avanir Pharmaceuticals, Inc.Nuedexta$85$16,25224 claims
AstraZenecaSymbicort$380$6,64427 claims
NovartisEntresto$37$5,95611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →